Undifferentiated upper gastrointestinal bleeding: Difference between revisions

(mimics)
No edit summary
Line 13: Line 13:
*ETOH abuse
*ETOH abuse
**Peptic ulcer disease, gastritis, varices
**Peptic ulcer disease, gastritis, varices
*Pseudo-melena
 
**Iron or bismuth use
===Physical Exam===
===Physical Exam===
*Tachycardia, hypotension
*Tachycardia, hypotension

Revision as of 16:27, 28 March 2015

Background

  • Bleeding originating proximal to ligament of Treitz

Diagnosis

History

  • Hematemesis
  • Coffee-ground emesis
  • Melena + age <50 suggests upper GI bleed
  • Vomiting + retching followed by hematemesis = Mallory-Weiss
  • Aortic graft = aortoenteric fistula
  • Meds
    • ASA, steroids, NSAIDs, anticoagulants
  • ETOH abuse
    • Peptic ulcer disease, gastritis, varices

Physical Exam

  • Tachycardia, hypotension
  • Liver disease
    • Spider angiomata, palmar erythema, jaundice, gynecomastia
  • Coagulopathy
    • Petechiae/purpura
  • ENT exam
    • Swallowed blood may result in coffee-ground emesis or melena
  • Rectal exam

Differential Diagnosis

Mimics of GI Bleeding

  • Hemoptysis
  • Vaginal/Urethra bleeding
  • Upper respiratory tract bleeding
  • Dietary (Iron, bismuth, beets)

Workup

  • 2 large bore IVs
  • Type and cross
  • CBC & serial Hb
  • Chemistry
    • BUN/Cr >30 suggests UGI if no hx of renal failure (incr absorption/digestion of hb)
  • Coags
  • LFTs
  • Guiac
  • ?ECG (if >50 yo or if suspicious for silent MI)
  • ?CXR (if suspect perforation)

NG Lavage Controversy

  • Pros
    • Positive aspirate proves strong evidence for an UGI source of bleeding
    • Can assess presence of ongoing active bleeding
    • Can prepare pt for endoscopy
  • Cons
    • Uncomfortable
    • Negative aspirate does not conclusively exclude UGI source
    • Provides useful information in only minority of pts w/o hematemesis
    • Erythromycin 200mg IV can provide equal endoscopy conditions as lavage

Treatment

  • Place 2 large bore IVs
  • PPI
    • Pantoprazole/esomeprazole 80mg x 1; then 8mg/hr
    • Reduces rate of endoscopic therapy but does not reduce morbidity or mortality
  • Antibiotics
    • Ceftriaxone 1gm daily x 7 days
    • Indicated for pts w/ cirrhosis or history of ETOH abuse (regardless of whether bleeding is variceal or not)
  • Erythromycin[1]
    • Achieves endoscopy conditions equal to lavage
    • 3mg/kg IV over 20-30min, 30-90min prior to endoscopy
  • Consider IVF
  • Blood products
    • Indications for PRBC transfusions:
      • Continued active bleeding
      • Failure to improve perfusion and vital signs after infusion of 2L NS
    • Varicele bleeding[2]
      • Cryopprecipitate to raise fibrinogen (goal >120mg/dL)
      • Platelets (goal >50-100k/μL
      • No role for FFP to correct the INR
  • Endoscopy

Balloon Tamponade with Sengstaken-Blakemore Tube

  • For life-threatening hemorrhage if endoscopy is not available)
  • Tube consists of gastric and esophageal balloons
    • First inflate gastric balloon; if bleeding continues inflate esophageal balloon
      • Esophageal pressure must not exceed 40-50 mmHg
  • Adverse reactions are frequent
    • Mucosal ulceration
    • Esophageal/gastric rupture
    • Tracheal compression (consider intubation prior to balloon insertion)

Treatments Not Supported by the Literature

  • No evidence to support octreotide use

Disposition

  • Consider admission for:
  1. Age >60yr
  2. Transfusion required
  3. Initial Sys BP < 100
  4. Red blood in NG lavage
  5. History of cirrhosis or ascites on exam
  6. History of vomiting red blood
  1. BUN <18
  2. Hb >13 (men), Hb >12 (women)
  3. Sys BP >110
  4. HR <100
  5. Pt did NOT present w/ melena
  6. Pt did NOT present w/ syncope
  7. No hepatic disease
  8. No cardiac failure

See Also

Lower GI Bleeding

Upper GI Bleed Guidelines

Source

  1. Pateron D, et al. Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial. Ann Emerg Med. 2011; 57(6):582-589.
  2. Intagliata NM, et al. Management of disordered hemostasis and coagulation in patients with cirrhosis. Clinical Liver Disease. 2014; 3(6):114-117.